We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




HPV Infection Identified In Self-Collected Vaginal Swabs

By LabMedica International staff writers
Posted on 19 May 2016
High risk, potentially cancer causing human papillomavirus infections (HPV) are common among women in the developing world, but self-sampling with vaginal swabs may provide materials that screen as accurately as the more labor-intensive approach using cervical samples obtained by clinicians.

Evaluating self-collected samples was a critical milestone as it would enable same-day screening and treatment. More...
Same-day treatment is needed in high-burden; low-income countries such as Papua New Guinea because when patients leave the clinic, it often becomes impossible to find them again, should their results show that they need treatment.

Scientists at The Kirby Institute (Sydney, Australia) conducted the first evaluation of self-collected vaginal specimens compared with clinician-collected cervical specimens for the detection of high-risk human papillomavirus (hrHPV) infection. Women aged 30 to 54 years attending two well woman clinics in Papua New Guinea were invited to participate and provided self-collected vaginal and clinician-collected cervical cytobrush specimens.

Both specimens were tested at point-of-care using the Xpert HPV test (Cepheid, Sunnyvale, CA, USA). Women were given their cervical test result the same day. Those with a positive hrHPV test and a positive examination on visual inspection of the cervix with acetic acid were offered same-day cervical cryotherapy. A total of 1,005 women were enrolled with 124 (12.3%) positive for any hrHPV infection. There was 99.4% overall percentage agreement (OPA) between vaginal and cervical tests for HPV-16, 98.5% OPA for HPV-18/45; 94.4% OPA for other hrHPV infections, and 93.4% OPA for all hrHPV types.

The authors concluded that self-collected vaginal specimens had excellent agreement with clinician-collected cervical specimens for the detection of hrHPV infection using the Xpert HPV test. This approach provides for the first time an opportunity to incorporate point-of-care hrHPV testing into clinical cervical screening algorithms in high-burden, low-income settings.

Andrew Vallely, PhD, an Associate Professor and corresponding author of the study said, “This is the first time there's been a direct comparison between self-collected vaginal swabs and clinician-collected cervical specimens using a screening device that can provide same day results.” The study was published online on April 13, 2016, in the Journal of Clinical Microbiology.

Related Links:
The Kirby Institute
Cepheid

Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
New
Portable POCT Blood Gas Analyzer
BD100
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.